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Abstract 
Mesenchymal stem cells (MSC) are highly immunosuppressive cells able to reduce chronic inflammation 
through the active release of mediators. Recently, we showed that glucocorticoid-induced leucine zipper (Gilz) 
expression by MSC is involved in their therapeutic effect by promoting the generation of regulatory T cells. 
However, the mechanisms underlying this pivotal role of Gilz remain elusive.  
Methods and Results In this study, we have uncovered evidence that Gilz modulates the phenotype and 
function of Th1 and Th17 cells likely by upregulating the level of Activin A and NO2 secreted by MSC. Adoptive 
transfer experiments sustained this Gilz-dependent suppressive effect of MSC on Th1 and Th17 cell functions. 
In immunoregulatory MSC, obtained by priming with IFN-γ and TNF-α, Gilz was translocated to the nucleus 
and bound to the promoters of inos and Activin βA to induce their expression. The increased expression of 
Activin A directly impacted on Th17 cells fate by repressing their differentiation program through the activation 
of Smad3/2 and enhancing IL-10 production.  
Conclusion Our results reveal how Gilz controls inos and Activin βA gene expression to ultimately assign 
immunoregulatory status to MSC able to repress the pathogenic Th17 cell differentiation program and uncover 
Activin A as a novel mediator of MSC in this process. 
Key words: Mesenchymal Stem Cells, Gilz, Activin A, Th17 cells, Immunosuppression. 
Introduction 
Th17 and Th1 cells are associated with the 
development of autoimmune diseases, including 
multiple sclerosis, rheumatoid arthritis, inflammatory 
bowel disease, and psoriasis [1-7]. Presently, the 
development of new approaches for the treatment of 
autoimmune disorders aims to target different aspects 
of the generation and function of Th17 and Th1 cells 
and promising advances rely on T cell plasticity [8]. 
Indeed, a strong relationship between the regulatory 
T cell (Treg) and Th17 lineages has been reported, in 
part based on the observation that, in the presence of 
IL-6, endogenous TGF-β can induce the 
differentiation of Treg cells into Th17 cells [9, 10]. The 
converse possibility to generate T cells with 
regulatory function from Th17 cells has also been 
described [11-13], even if less evidenced. Moreover, 
although less described, a plasticity of Th1 cells has 
also been proposed. Indeed, a high dose allergen 
tolerance was shown to induce clonal expansion of 
specific IL-10–secreting T cells, which may switch in 
vivo from existing Th1-like allergen-specific cells [14]. 
An increasing number of results have 
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highlighted the general capacity of polarized T cell 
subsets to adapt their phenotype and function in 
response to environmental tissue changes in the 
course of inflammatory reactions. In the attempts to 
force inflammatory Th17 cells to adopt a regulatory 
phenotype, mesenchymal stem cells (MSC) have been 
extensively explored due to their potent T cell 
suppressive properties, described both in vitro and in 
vivo a decade ago [15-17]. Among the possible 
mediators identified, inducible nitric oxide synthase 
(iNOS) [18] and prostaglandin E2 (PGE2) play 
important roles in murine MSC (mMSC) [19, 20]. MSC 
immunoregulatory functions are not constitutive, but 
require a priming step. Several cytokines, including 
IFN-γ, TNF-α, IL-1α, and IL-1β, trigger the expression 
of iNOS in mMSC [18]. iNOS production by mMSC 
exerts regulatory effects through the generation of 
toxic reactive nitrogen species, as well as through the 
nitration of other molecules proximate to its source of 
production [18]. MSC suppressive properties are in 
part mediated through the action of NO and result in 
the inhibition of CD4+ and CD8+ T cell proliferation as 
demonstrated both in vitro and in vivo [19, 21-23]. 
Using activated mouse CD4+ T cells under Th1 or 
Th17 skewing conditions in vitro, we previously 
reported that MSC inhibit the proliferation of Th1 and 
Th17 cells as well as their cytokine production. [24]. 
The generation of a Th1 cell population co-producing 
IFN-γ and IL-10 was recently proposed to be one of 
the mechanisms by which MSC exert their 
immunosuppressive properties [25]. More recently, 
we showed that MSC negative regulation of Th17 
responses restores the balance between Th17 and Treg 
cells in a murine model of autoimmune disease [26]. 
Although the mechanisms by which MSC exert their 
immunosuppressive effects have been the subject of 
many studies, the molecular regulation of the 
mediators responsible for MSC immunosuppressive 
effects, as well as the signaling pathways they activate 
in Th1 and Th17 cells remain largely unknown. 
Glucocorticoid-induced leucine zipper (Gilz or 
TSC22D3) is a protein that binds to and inhibits major 
pro-inflammatory transcription factors including 
nuclear factor κB (NF-κB) and activator protein 1 
(AP-1) [27]. Moreover, GILZ regulates signaling 
kinases Ras and Raf-1 leading to the inhibition of 
MAP kinases [28, 29]. A body of evidence indicates 
that Gilz is involved in the suppression of both innate 
and adaptive immune responses [27]. Overexpression 
of Gilz drives the development of regulatory dendritic 
cells (DC), and thereby prevents the production of 
pro-inflammatory cytokines by DC activated by CD40 
ligand [30]. Tolerance-inducing regulatory DC, which 
express Gilz, enhance the differentiation of 
IL-10-producing CD25highFoxp3+CTLA4+ Treg cells 
from naïve CD4+ T lymphocytes [31]. More recently, 
in an experimental model of arthritis, we have shown 
a pivotal role of Gilz in the therapeutic effects of MSC, 
through the generation of Treg cells bearing the 
CD4+RORγT+IL-17+IL-10+ signature [26]. In line with 
this study, the generation of Treg cells induced by 
MSC through the up-regulation of developmental 
endothelial locus-1 (Del-1) expression was also 
recently shown to be Gilz-dependent [32]. Although 
Gilz expression is required for MSC 
immunoregulatory activity, whether its expression 
directs the production of MSC immunosuppressive 
effect mediators remains to be demonstrated. 
Activin A, a member of the TGF-β superfamily, 
exerts immunomodulatory effects on DC and T cells. 
DC both secrete and respond to Activin A. Autocrine 
actions of Activin A potently reduce DC capacity to 
produce pro-inflammatory cytokines as well as their 
T-cell stimulatory potential [33]. Moreover, Activin A 
exerts immunomodulatory functions through the 
induction of CD4+Foxp3- IL-10+ and CD4+Foxp3- IL-10- 
Treg cells that inhibit Th1-driven responses [34]. 
Activin A receptor type IIA (ActRIIA) expression in 
CD4+ cells is dependent on TGF-β1 and IL-6 and is 
specific of and restricted to Th17 cells [35]. Although 
these studies suggest that ActRIIA acts as a marker for 
Th17 cells and that Activin A might regulate the 
Th17/Treg balance, how pathogenic Th17 fate is 
shaped by extrinsic signals delivered by primed MSC 
focusing on their capacity to release Activin A has not 
been addressed. 
In the present study, we investigated how Gilz, 
expressed by MSC, may affect the generation of Th1 
and Th17 cells and addressed the role of Activin A in 
this aspect. Going further, we investigated the 
intracellular regulation of MSC immunosuppressive 
mediators directed by Gilz, identifying its binding 
sites on the promoters of inos and Activin βA. Finally, 
we explored signaling pathways and transcriptional 
events that skew Th17 differentiation and function. 
Our findings indicate that the expression of Gilz by 
MSC is essential for the release of the suppressive 
molecules NO2 and Activin A. These effects underpin 
key aspects of the suppressive effects of MSC on T 
cells. 
 Results  
Gilz deficiency impairs MSC 
immunomodulatory function in vitro 
To assess the role of Gilz in MSC-mediated 
immunosuppressive function, we isolated MSC from 
bone marrow of Gilz-deficient mice and their 
wild-type Gilz+/+ littermates, referred to as Gilz-/- 
MSC and WT MSC respectively, as previously 
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described [23, 26, 36-38]. First, we investigated the 
phenotypic profile and multilineage differentiation 
potential of Gilz-/- MSC in vitro. Both WT MSC and 
Gilz-/- MSC were positive for Sca1, CD29, CD44 and 
CD105 and negative for CD11b and CD45 (Fig. S1A). 
The multipotent nature of the cells was confirmed by 
their capacity to differentiate into the three main 
lineages relying on the expression of lineage-specific 
markers quantified by RT-qPCR. WT and Gilz-/- MSC 
could be differentiated into chondrocytes, as shown 
by induction of collagen II (Col2b) and aggrecan 
(AGN), and into adipocytes, as revealed by increased 
expression of peroxysome proliferator-activated 
receptor (PPAR)-γ and fatty acid binding protein 4 
(FABP4) (Fig. S1B). WT and Gilz-/- MSC also 
differentiated into osteoblasts, expressing osteocalcin 
(OC) and alkaline phosphatase (ALP), although the 
expression of these genes was significantly 
diminished in Gilz-/- MSC (Fig. S1 B).  
Next, we assessed in vitro the 
immunosuppressive properties of WT and Gilz-/- 
MSC on ConA-stimulated splenocytes by determining 
the percentage of proliferating cells stained with 
CellTrace Violet (CTV). After 3 days of co-culture, WT 
MSC significantly inhibited T cell proliferation, but in 
contrast Gilz-/- MSC did not inhibit T cell proliferation 
(Fig. 1A-B). Since MSC have been described to 
negatively regulate both Th1 and Th17 responses, we 
analysed the effects of WT and Gilz-/- MSC on the 
polarization of naïve CD4+ T cells toward Th1 and 
Th17 lineage. The specific combinations of cytokines 
and neutralizing antibodies used for each lineage (see 
Materials and Methods) induced IFN-γ-producing 
cells (Th1) (Fig. 1C-F) and IL-17-producing cells 
(Th17), respectively, the latter cells also being positive 
for the Th17 lineage-specific transcription factor 
ROR-γT (Fig. 1G-J). The addition of WT MSC at day 0 
of T cell differentiation resulted in a significant 
decrease in the frequency of both Th1 and Th17 cells 
(Fig. 1C-D, G-H). In comparison, the capacity of Gilz-/- 
MSC to regulate CD4+ T cell differentiation into Th1 
or Th17 cells was significantly impaired (Fig. 1C-D, 
G-H). The role of Gilz on MSC regulatory effect was 
further evaluated by rescue experiments using Gilz-/- 
MSC transfected with plasmid pCDNA3.1-GILZ 
(Gilz-/- pl. Gilz) (Fig. S1C). While Gilz-/- pl. Gilz MSC 
were significantly more suppressive than WT MSC on 
CD4+ T cells induced to differentiate into Th17 (Fig. 
1J), they did not affect the generation of Th1 cells as 
compared to the Th1 differentiating cells cultured 
alone (Fig. 1F). These results reinforce the key role of 
Gilz on the capacity of MSC to repress CD4+ T cell 
differentiation toward Th17 lineage. We next assessed 
the effect of WT and Gilz-/- MSC on mature Th1 or 
Th17 cell function. WT and Gilz-/- MSC both 
significantly inhibited Th1 and Th17 cell cytokine 
expression after 3 days of co-culture (Fig. 1E, I). 
However, Gilz-/- MSC were significantly less effective 
in reducing Th1 signature cytokine production than 
WT MSC (Fig. 1E, I), while suppression of Th17 
signature cytokine production by WT and Gilz-/- MSC 
was similar. Additionally, we tested the effect of 
another corticosteroid, aldosterone, on the capacity of 
MSC to repress the differentiation of CD4+ T cells into 
Th1 or Th17 cells. First, we showed a dose-dependent 
increase of Gilz expression in human MSC treated 
with Aldosterone from a dose of 0.1 µM as compared 
to the control untreated MSC (Fig. S2A). Moreover, 
the pre-treatment of MSC with aldosterone, TNFα and 
IFNɣ significantly enhanced the suppressive effect of 
human MSC as compared to untreated MSC and MSC 
primed with either aldosterone or TNFα and IFNɣ on 
PHA-activated PBMC proliferation (Fig. S2B-C). In 
parallel, using mouse WT MSC, we observed that a 24 
h treatment with 1 µM of aldosterone significantly 
increased their immunoregulatory effect on CD4+ T 
cell induction to differentiate into Th1 (Fig. 1F) or 
Th17 cells (Fig. 1J). These results indicate that MSC 
immunosuppressive effects on Th1 and Th17 
differentiation, and mature Th1 cell function, are 
dependent on MSC expression of Gilz, but that MSC 
immunosuppressive effects on mature Th17 cells are 
independent of Gilz.  
Gilz deficiency impairs MSC 
immunomodulatory function in vivo  
We next assessed the immunosuppressive 
properties of WT and Gilz-/- MSC in vivo using an 
adoptive T cell transfer model. To determine whether 
Gilz expressed by MSC affects proliferation and 
differentiation of Th1 and Th17 subsets in secondary 
lymphoid organs, we adoptively transferred 
CTV-labeled HNT TCR transgenic Thy1.1+ CD4+ T 
cells specific for the influenza virus hemagglutinin 
(HA) into BALB/c mice. Mice were then immunized 
with HA peptide prior to MSC treatment (Fig. 2A). At 
day 4 after transfer, while we did not observe any 
difference in the percentage of CD4+CD90.1+ cells in 
the spleen of MSC-treated mice as compared to the 
control mice, a significant increase was observed in 
mice treated with Gilz-/- MSC (Fig. 2B). However, the 
proliferation rate of CD4+CD90.1+ cells was the same 
in the 3 different groups (Fig. 2C). Additionally, HNT 
Th1 and Th17 cells were detectable in spleens of 
immunized mice, with Th1 cells predominating (Fig. 
2D, F). Compared to non-treated mice, mice treated 
with WT MSC displayed a significant decrease in the 
frequency (Fig. 2D, F) and absolute numbers (Fig. 
2E,G) of Th1 and Th17 cells. In contrast, treatment 
with Gilz-/- MSC had no effect (Fig. 2D-G). Moreover, 
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we observed an increase in the frequency of donor 
CD90.1+ CD4+ T cells producing IL-10 in the spleens of 
mice treated with WT MSC, but not Gilz-/- MSC (Fig. 
2H-I). These results extend to in vivo conditions the 
requirement for Gilz for MSC to inhibit differentiation 
of naïve T cells into Th1 and Th17 cells.  
 
 
Figure 1. In vitro evaluation of the immunomodulatory properties of WT MSC and Gilz-/- MSC. (A-B) CTV-labelled splenocytes were stimulated with ConA and the proliferation 
of cells was measured by CTV dilution. Results are expressed as the percentage of ConA-induced proliferation, which was assigned a value of 100%, or as the percentage of CTV+ dividing cells. 
If not indicated otherwise, P values refer to ConA-activated samples. (C-J) Cell differentiation was assessed using T cells induced to differentiate into Th1 or Th17 cells in the absence (none) 
or presence of WT, Gilz-/- or Gilz-/-pl.Gilz MSC added at day 0 (CD4-Th1 or CD4-Th17, respectively) (C, D, F and G, H, J) or at day 4 of the differentiation process (mature Th1 or Th17, 
respectively) (E and I), at a MSC:T ratio of 1:10. For T cells characterization, intracellular detection of IFN-γ (Th1) or ROR-γT and IL-17 (Th17) was performed by flow cytometry (C and G, 
representative dot plots). (F and J) Evaluation of T cell differentiation toward the Th1 or Th17 lineages in the presence of MSC pre-treated for 24 h with 1 µM of aldosterone. (B, D, E, F, H, 
I and J) Mean values of n≥3 independent experiments. P values refer to the condition without MSC (none). * P < 0.05, ** P < 0.01. All error bars indicate SEM.  
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Figure 2. Gilz deficiency impaired the capacity of MSC to inhibit the generation of Th1 and Th17 in vivo. (A) Representative scheme of the in vivo experimental setting. BALB/c 
mice were adoptively transferred with naïve HNT Thy1.1+ CD4+ T cells and then immunized with HA peptide in complete Freund’s adjuvant. The same day, mice were either treated with the 
indicated MSC or left untreated. At day 4 after transfer, mice were sacrificed and donor T cells were identified in the spleen by virtue of the expression of the congenic Thy1.1 marker. (B) 
Percentage of CD4+CD90.1+ cells in the spleen of the mice. (C) Proliferation rate of CD4+CD90.1+ cells isolated from the spleen of mice. (D-E) Percentage (D) and absolute number (E) of Th1 
cells within the donor HNT Th1.1+ CD4+ T cell population from non-treated mice or mice treated with either WT or Gilz-/- MSC. (F-G) Percentage (F) and absolute number (G) of donor Th17 
cells in the spleen of BALB/c mice treated or not with either WT or Gilz-/- MSC. (H-I) Percentage of CD4+CD90.1+IL10+ (H) and absolute number of Tr1 cells (I) within the donor HNT Th1.1+ 
CD4+ T cell population from non-treated mice or mice treated with either WT or Gilz-/- MSC in the spleen. Dot plots are representative of 1 out of ≥3 independent experiments. Mean values 
of n≥3 independent experiments. * P < 0.05, ** P < 0.01.  
 
The secretion of MSC immunosuppressive 
mediators is Gilz-dependent  
 Since the critical role of IFN-γ in priming 
MSC-mediated suppression of immune cells is well 
established, we assessed the expression of the IFNγ 
receptor (IFNγR1) by WT and Gilz-/- MSC. FACS 
analysis indicated that IFNγR1 expression was higher 
in WT MSC (Fig. 3A). This low expression level of 
IFNγR1 in Gilz-/- MSC as compared to WT MSC could 
be related to their reduced immunosuppressive 
properties since IFNγR1 deficiency in MSC was 
described by their lack of immunosuppressive and 
therapeutic effects in an experimental model of 
GVHD [39]. Next, we analysed MSC production of 
PGE2 and NO2, which have been described to be 
associated with MSC immunomodulatory effects. WT 
and Gilz-/- MSC cultured for 3 days in the presence of 
differentiating CD4-Th1 or CD4-Th17 cells secreted 
similar levels of PGE2 (Fig. 3B). In contrast, after 
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co-culture with differentiating CD4-Th1 or CD4-Th17 
cells, Gilz-/- MSC secretion of NO2 was significantly 
lower than WT MSC (Fig. 3C). Finally, MSC secretion 
of Activin A was quantified. We observed abundant 
production of Activin A by WT MSC cultured in the 
presence of differentiating Th1 or Th17 cells, but 
significantly less Activin A was produced by Gilz-/- 
MSC under the same conditions (Fig. 3D). These 
results indicate that Gilz-dependent suppressive 
effect of MSC on T cell subsets is associated with 
Activin A and NO2 release.  
Identification of GILZ binding site motifs in 
Activin and inos promoter regions 
We next investigated potential mechanisms for 
Gilz modulation of MSC Activin A and NO2. First, we 
studied Gilz expression profile in MSC both in basal 
condition (none) and in response to activation with 
TNF-α and IFN-γ. We thus performed an 
immunofluorescence analysis of Gilz expression in 
MSC to assess the effect of MSC stimulation on Gilz 
expression level and cellular distribution. We found, 
in response to MSC activation, a significant increase of 
Gilz expression (Fig. 4A-B). Of note, the analysis of 
Gilz nuclear content revealed a significant increase of 
Gilz nuclear localization upon MSC stimulation as 
compared to non-activated cells (Fig. 4C). Next, we 
studied Gilz-specific transcriptional regulation of 
Activin βA and inos. To identify a putative DNA 
binding site, Mus musculus 5'UTR sequences for 
reported Gilz gene targets were retrieved from NCBI 
Nucleotide database [40]. The fasta sequences were 
used to look for over-represented motif enrichment 
between sequences using the Regulatory Sequence 
Analysis Tools, RSAT [41], as described in Materials 
and Methods. This analysis revealed the consensus 
sequence AACTT as the strongest binding site 
candidate (Fig. 4D). Accordingly, we designed 
primers covering each AACTT sequence in the 
regions close to the promoters of Activin βA and inos 
genes, and studied the recruitment of Gilz on these 
genes using chromatin immunoprecipitation (ChIP). 
In WT MSC, while no binding of Gilz at the inos 
promoter could be observed in unstimulated cells, 
activation with IFN-γ and TNF-α induced a massive 
recruitment of Gilz to the inos promoter at +22nt (Fig. 
4E). As expected, in Gilz-/- MSC, no significant 
recruitment of Gilz to the inos promoter was observed 
(Fig. 4E). The stimulation of WT MSC by IFN-γ and 
TNF-α also induced substantial recruitment of Gilz at 
the Activin βA promoter at -129 nt, compared to 
unstimulated cells in which no binding of Gilz on 
Activin βA promoter was observed (Fig. 4F). 
Altogether these results suggest that under MSC 
activation, cytosolic Gilz is translocated to the nucleus 
where it binds to the inos and Activin βA promoters to 
regulate the expression of these two key mediators of 
MSC immunosuppressive effects. 
 
 
Figure 3. Quantification of the mediators involved in MSC immunosuppressive properties. (A) Expression profile of IFNγR1 on WT and Gilz-/- MSC by FACS analysis. (B) PGE2 
assessment by ELISA in the 3-day culture supernatants of T cells induced to differentiate toward Th1 (grey bar) or Th17 (black bar) lineages, cultured alone or with MSC (WT or Gilz-/-). (C) 
Quantification of NO2 production using a modified Griess reaction in the 3-day culture supernatants of T cells induced to differentiate toward Th1 (grey bar) or Th17 (black bar) lineages 
cultured alone or with MSC (WT or Gilz-/-). (D) Activin A quantification by ELISA in the 3-day culture supernatants of T cells induced to differentiate toward Th1 (grey bar) or Th17 (black bar) 
lineages cultured alone or with MSC (WT or Gilz-/-). If not indicated, P values refer to the condition when the different T cell subsets were cultured without MSC (none). Mean values of n≥3 
independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001.  
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Figure 4. Study of Gilz DNA binding motifs in primed MSC. (A-C) Immunodetection of Gilz localization in MSC by confocal microscopy. The cells were visualized and photographed 
using a confocal microscope (Leica TCS SP5; Leica, Heidelberg, Germany). All the analyses were performed using the ImageJ program. For quantification, the fluorescence intensity reflecting 
Gilz expression profile (either total or nuclear) was quantified in different fields of each image for each condition. (D) The fasta sequences of the promoters of iNOS and Activin were used 
to look for overrepresented motif enrichment through the Motif Discovery oligo-analysis from Regulatory Sequence Analysis Tools (RSAT) that could be a possible target for Gilz binding, 
selecting oligomer lengths up to 5 bases and count on single strand parameters. (E-F) WT and Gilz-/- MSC were treated at 80% confluence either with 20 ng/mL IFN-γ and 10 ng/mL TNF-α. 
Then, the cells were harvested to perform chromatin immunoprecipitation (ChIP) experiments and the binding of Gilz on inos or Activin βa promoter regions was analyzed. Mean values of n≥3 
independent experiments. * P < 0.05. All error bars indicate SEM. 
 
Gilz-dependent secretion of Activin A by MSC 
impairs Th17 cell differentiation and function  
To determine whether Activin A produced by 
MSC is critical for their immunomodulatory effects on 
Th1 or Th17 polarization, we determined the 
expression of Activin receptors (ActRIIA and ActRIB) 
on these T cell subsets. Both Th1 and Th17 cells 
expressed ActRIIA and ActRIB, but receptor 
expression was significantly higher in Th17 cells (Fig. 
5A). We thus further investigated the role of Activin A 
on the suppressive effect of MSC on Th17 cells. CD4+ 
T cells under Th17 polarizing conditions were 
co-cultured with WT or Gilz-/- MSC for 3 days, in the 
presence or absence of Activin A. Compared to WT 
MSC, Gilz-/- MSC inhibition of Th17 differentiation, as 
estimated by IL-17 and ROR-ɣT expression, was 
significantly impaired (Fig. 5B). The addition of 
Activin A restored the ability of Gilz-/- MSC to inhibit 
Th17 differentiation (Fig. 5B) but had no effect on WT 
MSC (Fig. 5B). Of note, the addition of Activin A to 
CD4+ T cells significantly reduced the frequency of 
Th17 cells, but these effects were less than the effects 
of co-culture with WT MSC (Fig. 5B). To further study 
the key role of Activin A on MSC immunoregulatory 
role, we assessed the effect of Inhibin A, a natural 
Activin antagonist. The addition of Inhibin A in the 
co-culture of MSC with differentiating Th17 cells 
partially but significantly reversed the inhibitory 
effect of MSC on Th17 cell differentiation (Fig. 5C). 
These results suggest that Gilz-dependent secretion of 
Activin A by MSC provides a mechanism through 
which MSC inhibit Th17 cell differentiation. Like 
other members of the TGF-β family, Activin A signals 
via phosphorylation of Smad2 and/or Smad3 
proteins. Thus, we addressed the effects of MSC on 
the phosphorylation of these proteins in 
differentiating CD4-Th17 cells. Freshly isolated CD4+ 
T cells were cultured under Th17 skewing conditions 
with or without WT MSC and/or Activin A. Both WT 
MSC and Activin A enhanced Smad3/Smad2 
phosphorylation in T cells (Fig. 5D). However, no 
additive effect of Activin A and MSC was observed 
(Fig. 5D). We previously showed increased expression 
of TGF-β1 in MSC when cultured with T cells 
 Theranostics 2018, Vol. 8, Issue 3 
 
 
http://www.thno.org 
853 
undergoing Th17 differentiation [24]. Since Activin A 
acts as an enhancer of the TGF-β1-induced generation 
of iTreg, and that Treg and Th17 cells differentiate in a 
mutually exclusive fashion [42], we addressed 
whether IL-10-producing cells were generated under 
Th17-skewing conditions in presence of MSC and/or 
Activin A. In parallel with the suppression of Th17 
differentiation by culture with MSC or Activin A 
shown above, a significant increase in the percentage 
of T cells producing IL-10 was observed in response to 
MSC or Activin A (Fig. 5F). No effect on Foxp3 
expression level was observed in T cells cultured 
under the same conditions (Fig. 5E). Collectively, 
these data suggest that Activin A production by MSC 
represses the Th17 differentiation program 
accompanied by Smad3/2 activation and the 
generation of IL-10 producing T cells.  
Discussion 
In the present study, we investigated the 
mechanisms by which Gilz sustains the capacity of 
MSC to regulate Th1 and Th17 responses in vitro and 
in vivo. We show that this effect is mediated by an 
increased secretion of Activin A and NO2 by MSC. 
The priming of MSC with IFN-γ and TNF-α towards 
an immunosuppressive phenotype induces Gilz 
translocation from the cytosol to the nucleus, where it 
binds to Activin A and inos promoters. These data 
demonstrate a direct regulation of the transcription of 
these two genes associated with the 
immunosuppressive effect of Gilz in MSC. Moreover, 
our results show that Gilz-dependent release of 
Activin A by MSC induces the phosphorylation of 
Smad3/Smad2 in T cells, which promotes a switch 
from Th17 cells towards an IL-10 expressing 
regulatory T cell phenotype. We further demonstrated 
in vitro that the immunosuppressive effect of MSC on 
activated T cells undergoing Th1 or Th17 
differentiation, and on mature Th1 cells, is dependent 
on Gilz expression. In an adoptive transfer study, we 
showed that MSC expression of Gilz was required for 
the inhibition of the transferred Th1 and Th17 cells in 
immunized mice as well as for the increase in CD4+ T 
cells producing IL-10 in response to MSC. These 
results are in line with our previous study showing 
that MSC prevention of CIA progression by 
repressing both Th1 and Th17 responses in secondary 
lymphoid organs, enabling the generation of Treg 
cells producing IL-10, required the expression of Gilz 
by MSC [26].  
 
 
Figure 5. Role of Activin A on Th17 cell function. (A) The expression levels of the Activin A receptors ActRIIA and ActRIB were determined on Th1 and Th17 cells by RT-qPCR. (B-C) 
Cell differentiation was assessed in the absence or presence of WT MSC or Gilz-/- MSC added at day 0 (CD4-Th17) at a MSC:T ratio of 1:10. When indicated, 100 ng/mL of Activin A (B) or 
30 ng/mL of Inhibin A (C) was added to the T cells, alone or in combination with the MSC. The effect of Activin A or Inhibin A on the generation of Th17 cells was assessed by measuring the 
percentage of the IL-17 producing T-cells positive for ROR-γT under Th17 skewing conditions (CD4-Th17). CD4+ T cells were cultured without or with MSC, alone or in combination with 
Activin A. Unless otherwise indicated, P values refer to values obtained for CD4-Th17 when cultured alone. (D) Smad3/Smad2 phosphorylation in CD4+ T cells cultured for 3 h under Th17 
skewing conditions in absence or presence of WT MSC. When indicated, 100 ng/mL of Activin A was added to the T cells induced to differentiate, alone or in combination with the WT MSC. 
(E) Relative expression level of Foxp3 expressed by CD4+ T cells under Th17-skewing conditions cultured alone of in presence of MSC. (F) Percentage of T cells producing IL-10 after culture 
of CD4+ T cells under Th17-skewing conditions in presence of MSC or Activin A. Unless otherwise indicated, P values refer to values obtained for either CD4-Th1 or CD4-Th17 when cultured 
alone. * P < 0.05, ** P < 0.01, *** P < 0.001. Mean values of n≥3 independent experiments. 
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Figure 6. Representative scheme of Gilz nuclear translocation upon MSC activation. In the nucleus, Gilz binds to the binding sites in the promoter of the 
gene encoding inos and Activin and upregulates their expression levels. Activated MSC secrete high amounts of Activin A that binds to its receptors ActRIIA and ActRIB 
at the surface of T cells. Both Activin A and NO produced by primed MSC enhance Smad3/Smad2 phosphorylation in Th17 cells promoting IL-10 expression and 
secretion to the detriment of IL-17. 
 
Th17 differentiation, induced by low 
concentrations of TGF-β, enables T cells to express 
low levels of T-bet and thereby increases the tendency 
of Th17 cells to give rise to Th1 cells [43]. In contrast, 
high concentrations of TGF-β inhibit Th17 cell 
differentiation [44]. Therefore, depending on the 
concentration, TGF-β might exhibit different functions 
by either promoting Th17 or Treg cell differentiation 
[44, 45]. It was also reported that Activin A and TGF-β 
signalling pathways converge with regard to Smad2 
and 3 during generation of Treg cells [42]. We recently 
showed that CD4+ T cells under Th17-skewing 
conditions induce significant increases in TGF-β1 
expression in MSC [24]. In the present study we 
demonstrate that under the same conditions Activin A 
production by MSC was significantly enhanced. We 
hypothesized that TGF-β1 and Activin A produced by 
MSC co-cultured with T cells under Th17 skewing 
conditions inhibits Th17 differentiation, in favour of 
Treg. In line with this hypothesis, we showed in the 
present study that Activin A alone significantly 
repressed the Th17 molecular program of T cells. In 
parallel, we demonstrated that addition of Activin A 
to CD4+ T cells skewed their differentiation into Th17 
cells to a population of cells producing IL-10. In 
accordance with a study showing that Activin A 
induces the generation of Treg cells without changing 
the frequency of Foxp3-expressing CD25+CD4+ T cells 
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[34], we did not observe any change in Foxp3 
expression level in Activin A-induced CD4+ 
IL-10-producing cells. This suggests that the 
immunomodulatory effect of Activin A on Th17 cell 
responses relies on the induction of IL-10. Together, 
these results designate Activin A as an additional 
mediator of MSC immunosuppressive properties. 
Accordingly, Activin A treatment significantly 
decreased the frequency of Th17 cells, but to a lesser 
extent than the inhibition observed in response to 
co-culture with WT MSC, suggesting that factors 
produced by MSC additional to Activin A mediate 
their suppressive functions. However, Gilz-/- MSC 
lacked the effects of WT MSC on Th17 cell generation, 
confirming a requirement for Gilz in Th17 
suppression mediated by MSC. Finally, Activin A 
treatment restored the immunomodulatory properties 
of Gilz-/- MSC, suggesting that the regulation of the 
Th17/Treg balance by MSC might be in part mediated 
by a Gilz-dependent enhancement of Activin A 
production. Our findings introduce Activin A as a 
novel member in the family of these regulatory factors 
produced by MSC. 
To our knowledge, this study is the first one to 
report a Gilz-dependent regulation of Activin A and 
NO2 production by MSC. Thus, we provide evidence 
that the suppressive effects of MSC on T cells 
undergoing Th1 or Th17 differentiation and on 
mature Th1 cells are mandatory Gilz-dependent. 
Indeed, we dissected and highlighted a mechanism 
explaining the role of Gilz in MSC 
immunosuppressive effects on T cells. We 
demonstrated that, in inflammatory conditions, 
factors from the microenvironment such as TNF-α 
and IFN-γ, induce in MSC the translocation of Gilz 
protein from the cytosolic to the nuclear compartment 
where it directly modulates the expression of Activin 
A and NO2 by binding specific motifs in the 
promoters of Activin βA and inos, respectively. In 
primed MSC, Gilz might act as a molecular switch of 
Activin A synthesis that after its secretion by MSC is 
able to bind to its receptors ActRIIA and ActRIB 
present at the surface of Th17 cells. By signalling via 
the Smad2 and/or Smad3 protein pathway, Activin A 
ultimately induces the transcription of IL-10 in Th17 
cells and inhibition of IL-17, switching the 
differentiation of the pro-inflammatory Th17 lineage 
toward a Treg cell phenotype and function. In 
conclusion, this study, by expanding the knowledge 
on the molecular mechanisms that mediate the 
immunosuppressive effects of MSC on T cells, 
suggests a new paradigm of immunomodulation by 
MSC. The inhibition of Th17 cell development by 
Gilz-expressing MSC offers a promising therapeutic 
strategy for the treatment of various autoimmune 
diseases that are mediated by Th17 cells. 
Materials and Methods 
Ethics statement 
All animal studies were conducted according to 
the European guidelines for animal welfare 
(2010/63/EU). Protocols were approved by the 
Languedoc Roussillon Institutional Animal Care and 
Use Committee (CEEA-LR-12163).  
Mice  
DBA/1 and BALB/c mice were purchased from 
Charles River Laboratories. Gilz-deficient mice have 
been previously described [46]. HNT TCR (class II 
restricted and recognizes its epitope PR/8 HA 
126–138 in the context of I-Ad) transgenic mice [47] 
were backcrossed with BALB/c mice for more than 10 
generations. In addition, they were crossed with 
BALB/c Thy1.1+/+ congenic mice for two generations 
to achieve homozygosity for Thy1.1. Mice were 
maintained under specific pathogen free conditions at 
the animal facility of the Institute for Neurosciences of 
Montpellier. 
Isolation and characterization of murine 
mesenchymal stem cells 
For MSC isolation, bones from littermate 
C57BL/6 wild-type (WT MSC) and Gilz-deficient 
mice (Gilz-/- MSC) were used. Bone marrow were 
collected by flushing femurs and tibias and the cell 
suspension was plated at a concentration of 1x106 
cells/cm2 in a modified minimum essential Eagle's 
medium (MEM) supplemented with 10% fetal bovine 
serum (FBS) (Hyclone, Thermo Fisher Scientific), 2 
mM glutamine, 100 U/mL penicillin, 100 mg/mL 
streptomycin (Lonza, Levallois-Perret, France) and 2 
ng/mL human basic fibroblast growth factor (bFGF) 
(R&D Systems, Lille, France). MSC were then 
characterized by the expression of the typical 
mesodermal antigens CD29, Sca1 and CD44 and the 
absence of the hematopoietic markers CD45 and 
CD11b (all monoclonal antibodies from BD 
Pharmingen) by flow cytometry (FACS). Functionally, 
the differentiation potential of WT MSC and Gilz-/- 
MSC differentiation potential into adipocytes, 
chondrocytes and osteoblasts was assessed by 
RT-qPCR using specific primers for each lineage. 
Indeed, to assess the chondrogenic potential, we used 
the primers for type II collagen (Col IIB) and aggrecan 
(AGN) detection, to assess the adipogenic potential, 
we used the primers for fatty acid binding protein 4 
(FABP4) and peroxisome proliferator-activated 
receptor- (PPAR)γ detection, and to assess the 
osteogenic potential, we used the primers for 
osteocalcin (OC) and Alcaline Phosphatase (ALP).  
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Rescue experiments 
The plasmid pCDNA3.1-GILZ (kindly provided 
by Carlo Riccardi) was transfected in Gilz-/- MSC 
(Gilz-/-pl.Gilz MSC) using Lipofectamine according to 
the recommendations of the manufacturer 
(Invitrogen). 
T cell isolation 
CD4+ T cells were purified from freshly isolated 
splenocytes from female DBA/1 mice or from the 
lymph nodes (LN) and spleen of HNT TCR Thy1.1 
transgenic mice using the Dynal® CD4 negative 
isolation kit according to the manufacturer’s 
instructions (Invitrogen).  
In vitro T cell differentiation and co-culture 
with MSC 
Purified CD4+ T cells were then activated with 
anti-mouse CD3/CD28 Dynabeads (Invitrogen) and 
cultured in complete Iscove's Modified Dulbecco's 
Media (IMDM) containing 10% of heat-inactivated 
FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 
µg/mL streptomycin, 0.1 mM non-essential amino 
acids, 1 mM sodium pyruvate, 20 mM HEPES and 50 
µM of beta-mercaptoethanol (Invitrogen). Th1 
differentiation was induced by adding 20 ng/mL 
IL-12 and 2.5 µg/mL anti–IL-4 monoclonal antibody, 
and Th17 differentiation was induced with 2.5 ng/mL 
TGF-β1, 50 ng/mL IL-6 and 2.5 µg/mL of both 
anti-IFN-γ, and anti–IL-4 capture antibodies (R&D 
Systems). Where indicated, 100 ng/mL of 
recombinant Activin A or 30 ng/mL of recombinant 
Inhibin A (R&D Systems) was added. For the 
pre-treatment of MSC with aldosterone (Sigma 
Aldrich) at 0.01, 0.1 and 1 µM, the drug was added to 
the MSC media for 24 h and then removed prior to 
co-culture of MSC with activated T cells. MSC were 
co-cultured with activated CD4+ T cells during 
differentiation towards Th1 or Th17 cells (CD4-Th1 or 
CD4-Th17), or with mature Th1 or Th17 cells (at day 4 
of the differentiation processes). WT MSC or Gilz-/- 
MSC were added at day 0 or day 4, respectively, at a 
1:10 MSC:T cells ratio. After 3 days of co-culture, the 
differentiation of T-cells was tested by intracellular 
staining using FACS analysis respectively.  
Proliferation assay 
Fresh splenocytes or purified CD4+ T cells were 
labeled with CellTrace Violet (CTV) (Life-Technology, 
Saint Aubin, France) prior to being cocultured with or 
without WT MSC or Gilz-/- MSC at a 1:10 MSC:T cell 
ratio in presence of 5 µg/mL of concanavalin (ConA) 
(Sigma-Aldrich). After 72 h, the proliferation of T cells 
was quantified by flow cytometry.  
RT-qPCR analysis 
Total RNA from WT MSC or Gilz-/- MSC were 
extracted using the RNeasy mini kit (Qiagen S.A.). 
RNA (500 ng) was reverse transcribed using the 
Multiscribe reverse transcriptase (Applied 
Biosystems). Real-time RT-qPCR was performed 
using the SYBR Green I Master kit and a LightCycler® 
480 Detection system, following the manufacturer’s 
recommendations (Roche Applied Science). Specific 
primers for Gilz, Col2b, AGN, FABP4, PPAR-γ, OC 
and ALP were designed using the Primer3 software. 
Data were normalized to the housekeeping gene 
ribosomal protein S9 (RPS9). Values are expressed as 
relative mRNA level of specific gene expression as 
obtained using the 2−ΔCt formulae. 
Activin A, Prostaglandin E2 and NO2 
quantification 
The enzyme-linked immunosorbent assay 
(ELISA) for Activin A (R&D Systems) and the Enzyme 
Immunoassay kit for Prostaglandin E2 (PGE2) (Ann 
Arbor, Souffelweyersheim) were used. 
NO2 production was quantified using a modified 
Griess reagent (Sigma-Aldrich).  
Gilz DNA binding motif identification  
Briefly, the Mus musculus partial 5'UTR 
sequence for iNOS, Nos2, inducible nitric oxide 
synthase and Activin beta A subunit were retrieved 
from NCBI Nucleotide database (Nucleotide 
GeneBank codes U58677.1, L23806.1, AF427516.1 & 
D83214.2) [40]. The fasta sequences were used to look 
for overrepresented motif enrichment, through the 
Motif Discovery oligo-analysis provide by the 
Regulatory Sequence Analysis Tools, RSAT [41], 
selecting oligomer lengths up to 5 bases and count on 
single strand parameters. The motif with best 
expected relative frequency between the sequences 
was chosen.  
Chromatin immunoprecipitation (ChIP) 
MSC were treated at 80% confluence either with 
20 ng/mL IFN-γ and 10 ng/mL TNF-α or with 
supernatant collected from Th1 or Th17 cells for 30 
min. The cells were harvested and ChIP analysis was 
performed with a ChIP-IT® High Sensitivity kit 
(Active Motif) according to the manufacturer´s 
instructions. The following antibodies were used: 
mouse anti-Gilz (ab55015, Abcam) and normal mouse 
IgG (sc-2025, Santa Cruz, Heidelberg, Germany). 
Primers for inhibinβA were forward: 5’-CTGGAAAA 
ACGAGTCATCTGCTG-3’, reverse: 5’-GTCAGAGCT 
GTCTGAATTCCTCT-3’; and for inos were forward: 
5’-CTGGTTTGAAACTTCTCAGCCAC-3’, reverse: 
5’-CAACGTTCTCCGTTCTCTTGCAG-3’. 
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Phospho-Smad3 and 2 immunoassays 
Phospho-Smad3 and Smad2 were quantified 
with an ELISA-based assay using fluorogenic 
substrates kit (R&D Systems). T-cells were fixed with 
paraformaldehyde 8% and permeabilized following 
the manufacturer’s instructions. Protein 
phosphorylation was finally measured using a double 
immunoenzymatic labeling procedure allowing the 
total protein and the phosphorylated protein to be 
quantified. Normalized results were determined by 
dividing the phospho-Smad3/Smad2 fluorescence 
measured at 600 nm by the total Smad3/Smad2 
fluorescence at 450 nm for each sample. 
Adoptive transfer experiments 
Isolated T cells were labeled with 2 μM of Cell 
Trace Violet (CTV) (CellTrace CTV Cell Proliferation 
Kit, Invitrogen) in PBS for 10 min at 37°C. Then, 
3,5x106 labeled HNT TCR Thy1.1+ CD4+ T cells were 
injected i.v. in PBS into female BALB/c mice (8-10 
weeks old). In order to immunize the recipient mice, 
50 μg of influenza PR/8 HA 126–138 peptide was 
injected intradermaly in complete freund adjuvant. 2 
h after immunization, groups of mice were either left 
untreated or injected i.v. with 1x106 WT or Gilz-/- 
derived MSCs. 
Flow cytometry analysis 
After 3 days of culture or co-culture with MSC, T 
cells were stimulated for 4 h with 50 ng/mL 
phorbolmyristate acetate (PMA) (Sigma-Aldrich), 1 
µg/mL ionomycin (Sigma-Aldrich), and 10 µg/mL 
brefeldin A (Sigma-Aldrich). For surface antigen 
staining, cells were first incubated with antibodies 
against CD4-APC-H7 and CD25-APC (BD 
Pharmingen) for 20 min at 4°C in the dark. They were 
then fixed overnight at 4°C with the FoxP3 staining 
buffer set (eBioscience) in order to perform 
intracellular staining. Then, cells were incubated for 
30 min with anti-IFN-γ-PE, IL-17-Percp5.5, IL-10-PE 
(BD Pharmingen), ROR-γT-APC and FoxP3-FITC 
antibodies (eBioscience). For in vivo experiments, four 
days after injection of cells and immunization, LN and 
spleen from the recipient mice were collected and 
processed separately to obtain a single cell suspension 
by mechanical disruption on 40 μm filters (Corning) 
in PBS containing 2% FCS 0.02% sodium azide at 4°C. 
After counting, LN cells and splenocytes were 
cultured for 4 h in the prescence of PMA, Ionomycin 
and Brefeldin A (Sigma Aldrich) at 37º, 5% CO2. Then, 
cells were stained using specific surface antibodies 
against CD4 and CD90.1 (BD Pharmingen). For 
intracellular detection, the specific Fixation and 
Permeabilization Kit (eBioscience) was used following 
the manufacturer’s instructions. Specific antibodies 
were used against Foxp3, IFN-γ, IL-17 and IL-10 in 
order to identify different subpopulations of T-CD4 
cells. Acquisition was finally performed with the 
FACS Canto II and analyzed using the BD FACSdiva 
software (BD Pharmingen).  
Statistical analysis 
Results are expressed as the mean ± (SEM). 
Generated P values and post-analyses were 
performed first with Kruskal–Wallis test to analyze 
differences between all the groups and then using the 
Mann–Whitney test to compare two groups. P-values 
< 0.05 (*), P < 0.01 (**) or P < 0.001 (***) were 
considered statistically signiﬁcant. Analysis and 
graphical representation were performed using 
Graph-Pad PrismTM software (Graphpad). 
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